Everest Medicines Ltd
Everest Medicines's GHG Emissions Data Preview
In 2023, Everest Medicines completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Everest Medicines has also provided a category-level breakdown for 2 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2023 | 2022 | 2021 | 2020 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
a
b
a
bCreate your Tracenable account today and download up to 5 company datasets of your choice for free. No credit card required.
Verified Sources Behind Everest Medicines’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Everest Medicines’s data sources below and access millions more through our Disclosure Search.
Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.
Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.
Insights into Everest Medicines's Operational Emissions
In 2023, the total operational greenhouse gas (GHG) emissions of Everest Medicines amounted to 5,618.61 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Everest Medicines increased by 848.54%, suggesting that the company faced challenges in reducing its emissions from its core operations. a b
Everest Medicines's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Everest Medicines's Scope 1 emissions?
In 2023, the total Scope 1 emissions of Everest Medicines were 0.42 metric tons of CO₂ equivalent (tCO₂e). a
What are Everest Medicines's Scope 2 emissions?
In 2023, Everest Medicines reported Scope 2 greenhouse gas (GHG) emissions of 5,618.19 tCO₂e without specifying the calculation method. a
Has Everest Medicines reduced its Scope 2 emissions over time?
Compared to the previous year (2022), Everest Medicines's Scope 2 emissions (Unspecified Calculation Method) rose by 848.47% in 2023, suggesting that the company faced challenges in reducing emissions from purchased electricity and energy a b
What methodology does Everest Medicines use for Scope 2 reporting?
In 2023, Everest Medicines reported its Scope 2 emissions using an unspecified methodology. a
Everest Medicines's Scope 2 Emissions Over Time
- Total Scope 2 (Unspecified Calculation Method)
Insights into Everest Medicines's Value Chain Emissions
In 2023, Everest Medicines reported 493.71 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain. a
The 2023 disclosure of Everest Medicines includes a breakdown across 2 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2022, demonstrating consistent Scope 3 emissions reporting coverage year over year. a
Everest Medicines's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Everest Medicines's Scope 3 emissions?
In 2023, Everest Medicines reported total Scope 3 emissions of 493.71 metric tons of CO₂ equivalent (tCO₂e). a
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment. a
Compared to the previous year (2022), Everest Medicines's Scope 3 emissions increased by 1,044.97%, suggesting that the company faced challenges in reducing emissions across its value chain. a b
What categories of Scope 3 emissions does Everest Medicines disclose?
In 2023, Everest Medicines reported emissions for 2 out of the 15 Scope 3 categories defined by the GHG Protocol. a
The limited disclosure restricts visibility into specific emission sources across the company's value chain.
What are the main sources of Everest Medicines's Scope 3 emissions?
In 2023, the largest contributors to Everest Medicines's Scope 3 emissions were: a
- Business Travel (Cat. 6): 390.11 tCO₂e (79.02%)
- Fuel- and Energy-Related Services (Cat. 3): 103.6 tCO₂e (20.98%)
Everest Medicines's Scope 3 Emissions by Categories
Insights into Everest Medicines's Total Carbon Footprint
In 2023, Everest Medicines reported a total carbon footprint of 6,112.32 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 861.87% increase compared to 2022, suggesting a rise in emissions across its operations or value chain. a b
The largest contributor to Everest Medicines's total carbon footprint was Scope 2 emissions, accounting for 91.92% of the company's total carbon footprint, followed by Scope 3 emissions at 8.08%. a